Breaking Finance News

RBC Capital Markets announced Valeant Pharmaceuticals (TSE:VRX), boosting its stock price target to $39.00 today

Yesterday Valeant Pharmaceuticals (TSE:VRX) traded 0.70% higher at $22.89. The company’s 50-day moving average is $26.49 and its 200-day moving average is $31.56. The last stock close price is down -26.74% from the 200-day moving average, compared to the S&P 500 which has decreased -0.03% over the same time. 193,473 shares of the stock were exchanged, down from an average trading volume of 1,178,960

In a report released on 11/28/2016 RBC Capital Markets upped the price target of Valeant Pharmaceuticals (TSE:VRX) to $39.00 indicating a possible upside of 0.70%.

Previously on 11/18/2016, RBC Capital Markets reported about Valeant Pharmaceuticals (TSE:VRX) raised the target price from $0.00 to $39.00. At the time, this indicated a possible upside of 0.61%.

See Chart Below

Valeant Pharmaceuticals (TSE:VRX)

Valeant Pharmaceuticals has a 52 week low of $18.41 and a 52 week high of $165.77 The company’s market cap is currently $0.

In addition to RBC Capital Markets reporting its target price, a total of 6 firms have reported on the stock. The consensus target price is $25.42 with 1 firm rating the stock a strong buy, 0 firms rating the stock a buy, 5 firms rating the stock a hold, 1 firm rating the stock a underperform, and finally 0 firms rating the stock a sell.

About Valeant Pharmaceuticals (TSE:VRX)

Valeant Pharmaceuticals International, Inc. is a pharmaceutical and medical device company. The Company is engaged in developing and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices). It operates through two segments: Developed markets and Emerging markets. In the Developed Markets segment, it focuses on the areas of dermatology, neurology, gastrointestinal disorders, and eye health therapeutic classes. In the Emerging Markets segment, it focuses on primarily on branded generics, OTC products and medical devices. Its pharmaceutical products include Xifaxan, Solodyn and Glumetza. Its OTC products include PreserVision, CeraVe, Biotrue and Boston. Its other generic products include Latanoprost and Metronidazole. Its ophthalmic surgical products include intraocular lenses, such as Akreos, enVista, Crystalens and Trulign.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.